Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Harvard Business School
AstraZeneca
Johnson and Johnson
Mallinckrodt

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,061,029

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,061,029 protect, and when does it expire?

Patent 9,061,029 protects TASIGNA and is included in one NDA.

Protection for TASIGNA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in thirty-two countries.

Summary for Patent: 9,061,029
Title:Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Abstract: The present invention relates to a regimen for the administration of a pyrimidylaminobenzamide of formula I ##STR00001## wherein the radicals as defined herein, or of a pharmaceutically acceptable salt thereof, for the treatment of proliferative disorders, particularly solid and liquid tumors, and other pathological conditions mediated by the Bcr-Abl oncoprotein, the cell transmembrane tyrosine kinase receptor c-Kit, DDR1 (discoidin domain receptor 1), DDR2 (discoidin domain receptor 2) or PDGF-R (platelet derived growth factor receptor) kinase activity, wherein the pyrimidylaminobenzamide of formula I and, optionally, pharmaceutically acceptable carriers, are dispersed in a fruit preparation.
Inventor(s): Gallagher; Neil (Basel, CH), Yin; Ophelia (Denville, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:13/509,626
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 9,061,029

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis TASIGNA nilotinib hydrochloride CAPSULE;ORAL 022068-003 Mar 22, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Novartis TASIGNA nilotinib hydrochloride CAPSULE;ORAL 022068-002 Jun 17, 2010 RX Yes No   Start Trial   Start Trial Y   Start Trial
Novartis TASIGNA nilotinib hydrochloride CAPSULE;ORAL 022068-001 Oct 29, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,061,029

PCT Information
PCT FiledNovember 17, 2010PCT Application Number:PCT/US2010/056926
PCT Publication Date:May 26, 2011PCT Publication Number: WO2011/062927

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.